SCH-442,416
From Self-sufficiency
| SCH-442,416 | |
|---|---|
| File:SCH442416 structure.png | |
| 2-(2-furyl)-7-[3-(4-methoxyphenyl)propyl]-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine | |
| Other names SCH-442,416 | |
| style="background: #F8EABA; text-align: center;" colspan="2" | Identifiers | |
| CAS number | 316173-57-6 |
| SMILES | Script error: No such module "collapsible list". |
| style="background: #F8EABA; text-align: center;" colspan="2" | Properties | |
| Molecular formula | C20H19N7O2 |
| Molar mass | 389.410 |
| Except where noted otherwise, data are given for materials in their standard state (at 25 °C, 100 kPa) | |
| Infobox references | |
SCH-442,416 is a highly selective adenosine A2a subtype receptor antagonist. It is widely used in its 11C radiolabelled form to map the distribution of A2a receptors in the brain, where they are mainly found in the striatum, nucleus accumbens, and olfactory tubercle.[1] Given its distribution in the brain, A2a receptors have been investigated for the treatment of various neurological disorders, and SCH-442,416 has shown promise in treatment of depression,[2] Parkinson's disease,[3] and catalepsy.[4]
 |
This pharmacology-related article is a stub. You can help ssf by expanding it. |
References
Cite error: Invalid <references> tag;
parameter "group" is allowed only.
<references />, or <references group="..." />External links
- ↑ Moresco RM, Todde S, Belloli S, Simonelli P, Panzacchi A, Rigamonti M, Galli-Kienle M, Fazio F. In vivo imaging of adenosine A2A receptors in rat and primate brain using [11C]SCH442416. European Journal of Nuclear Medicine and Molecular Imaging. 2005 Apr;32(4):405-13. PMID 15549298
- ↑ El Yacoubi M, Costentin J, Vaugeois JM. Adenosine A2A receptors and depression. Neurology. 2003 Dec 9;61(11 Suppl 6):S82-7. PMID 14663017
- ↑ Matsuya T, Takuma K, Sato K, Asai M, Murakami Y, Miyoshi S, Noda A, Nagai T, Mizoguchi H, Nishimura S, Yamada K. Synergistic effects of adenosine A2A antagonist and L-DOPA on rotational behaviors in 6-hydroxydopamine-induced hemi-Parkinsonian mouse model. Journal of Pharmacological Sciences. 2007 Mar;103(3):329-32. PMID 17341841
- ↑ Mihara T, Noda A, Arai H, Mihara K, Iwashita A, Murakami Y, Matsuya T, Miyoshi S, Nishimura S, Matsuoka N. Brain adenosine A2A receptor occupancy by a novel A1/A2A receptor antagonist, ASP5854, in rhesus monkeys: relationship to anticataleptic effect. Journal of Nuclear Medicine. 2008 Jul;49(7):1183-8. PMID 18552135
